Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS

Treatment of Guillain‐Barré syndrome with a standard course of high‐dose intravenous immunoglobulin (IVIg) results in a variable clinical recovery which is associated with changes in serum IgG levels after treatment. The neonatal Fc‐receptor protects IgG from degradation, and a genetic polymorphism...

Descripción completa

Detalles Bibliográficos
Autores principales: Fokkink, Willem‐Jan R., Haarman, Annechien E. G., Tio‐Gillen, Anne P., van Rijs, Wouter, Huizinga, Ruth, van Doorn, Pieter A., Jacobs, Bart C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931719/
https://www.ncbi.nlm.nih.gov/pubmed/27386503
http://dx.doi.org/10.1002/acn3.307
_version_ 1782440953320046592
author Fokkink, Willem‐Jan R.
Haarman, Annechien E. G.
Tio‐Gillen, Anne P.
van Rijs, Wouter
Huizinga, Ruth
van Doorn, Pieter A.
Jacobs, Bart C.
author_facet Fokkink, Willem‐Jan R.
Haarman, Annechien E. G.
Tio‐Gillen, Anne P.
van Rijs, Wouter
Huizinga, Ruth
van Doorn, Pieter A.
Jacobs, Bart C.
author_sort Fokkink, Willem‐Jan R.
collection PubMed
description Treatment of Guillain‐Barré syndrome with a standard course of high‐dose intravenous immunoglobulin (IVIg) results in a variable clinical recovery which is associated with changes in serum IgG levels after treatment. The neonatal Fc‐receptor protects IgG from degradation, and a genetic polymorphism in its promoter region that influences the expression of Fc‐receptor, may in part explain the variation in IgG levels and outcome. This polymorphism was determined by polymerase chain reaction in a cohort of 257 patients with Guillain‐Barré syndrome treated with IVIg. We could not demonstrate a relation between this polymorphism, the pharmacokinetics of IVIg, or the clinical course and outcome.
format Online
Article
Text
id pubmed-4931719
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-49317192016-07-06 Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS Fokkink, Willem‐Jan R. Haarman, Annechien E. G. Tio‐Gillen, Anne P. van Rijs, Wouter Huizinga, Ruth van Doorn, Pieter A. Jacobs, Bart C. Ann Clin Transl Neurol Brief Communications Treatment of Guillain‐Barré syndrome with a standard course of high‐dose intravenous immunoglobulin (IVIg) results in a variable clinical recovery which is associated with changes in serum IgG levels after treatment. The neonatal Fc‐receptor protects IgG from degradation, and a genetic polymorphism in its promoter region that influences the expression of Fc‐receptor, may in part explain the variation in IgG levels and outcome. This polymorphism was determined by polymerase chain reaction in a cohort of 257 patients with Guillain‐Barré syndrome treated with IVIg. We could not demonstrate a relation between this polymorphism, the pharmacokinetics of IVIg, or the clinical course and outcome. John Wiley and Sons Inc. 2016-05-17 /pmc/articles/PMC4931719/ /pubmed/27386503 http://dx.doi.org/10.1002/acn3.307 Text en © 2016 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Brief Communications
Fokkink, Willem‐Jan R.
Haarman, Annechien E. G.
Tio‐Gillen, Anne P.
van Rijs, Wouter
Huizinga, Ruth
van Doorn, Pieter A.
Jacobs, Bart C.
Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS
title Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS
title_full Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS
title_fullStr Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS
title_full_unstemmed Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS
title_short Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS
title_sort neonatal fc receptor promoter gene polymorphism does not predict pharmacokinetics of ivig or the clinical course of gbs
topic Brief Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931719/
https://www.ncbi.nlm.nih.gov/pubmed/27386503
http://dx.doi.org/10.1002/acn3.307
work_keys_str_mv AT fokkinkwillemjanr neonatalfcreceptorpromotergenepolymorphismdoesnotpredictpharmacokineticsofivigortheclinicalcourseofgbs
AT haarmanannechieneg neonatalfcreceptorpromotergenepolymorphismdoesnotpredictpharmacokineticsofivigortheclinicalcourseofgbs
AT tiogillenannep neonatalfcreceptorpromotergenepolymorphismdoesnotpredictpharmacokineticsofivigortheclinicalcourseofgbs
AT vanrijswouter neonatalfcreceptorpromotergenepolymorphismdoesnotpredictpharmacokineticsofivigortheclinicalcourseofgbs
AT huizingaruth neonatalfcreceptorpromotergenepolymorphismdoesnotpredictpharmacokineticsofivigortheclinicalcourseofgbs
AT vandoornpietera neonatalfcreceptorpromotergenepolymorphismdoesnotpredictpharmacokineticsofivigortheclinicalcourseofgbs
AT jacobsbartc neonatalfcreceptorpromotergenepolymorphismdoesnotpredictpharmacokineticsofivigortheclinicalcourseofgbs

Ejemplares similares